Seattle Biotech CounterX Therapeutics Inks Licensing Deal for Opioid Abuse Treatments

CounterX Therapeutics signed an exclusive licensing agreement with the University of Washington and the University of Minnesota for patents targeting opioid abuse. The deal will help advance its lead drug CTRX-101, an injectable antibody that binds to fentanyl and blocks its effects, into clinical trials expected this year. The patents also cover therapeutic approaches and vaccine candidates aimed at preventing relapse.